Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMF3G06)

Drug Name
NSC-319745 Drug Info
Synonyms
61629-60-5; HB 093; NSC-319745; BRN 2168571; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)hydrocinnamic acid; 3-[4-[2-[(5-CHLORO-2-METHOXY-BENZOYL)AMINO]ETHYL]PHENYL]PROPANOIC ACID; 3-(4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)phenyl)-propionsaeure [German]; 3-[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]propanoic acid; HYDROCINNAMIC ACID, 4-(2-((5-CHLORO-2-METHOXYBENZOYL)AMINO)ETHYL)-; AC1L2AFL; CHEMBL597112; SCHEMBL11481071; CTK5B3505; DTXSID00210642; AIEFQKOARQRACO-UHFFFAOYSA-N; ZINC1572211; HB-093; NSC319745
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
43709
CAS Number
CAS 61629-60-5
TTD Drug ID
DMF3G06

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [1]
PMID27376512-Compound-MTC-424 DMGNRZU N. A. N. A. Patented [2]
PMID27376512-Compound-MTC-427 DMWXEZD N. A. N. A. Patented [2]
PMID27376512-Compound-MTC-422 DM1MVQD N. A. N. A. Patented [2]
PMID27376512-Compound-MTC-423 DM9RSDX N. A. N. A. Patented [2]
(L-)-S-adenosyl-L-homocysteine DMDUN83 Discovery agent N.A. Investigative [3]
NSC-622445 DME35CB Discovery agent N.A. Investigative [1]
NSC-622444 DMM5UT9 Discovery agent N.A. Investigative [1]
NSC-138419 DMH684Q Discovery agent N.A. Investigative [1]
NSC-348926 DM3TDEO Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting DNA [cytosine-5]-methyltransferase (DNMT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Azacitidine DMTA5OE Acute myelogenous leukaemia 2A41 Approved [4]
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [1]
S-110 DMXY34J Acute myeloid leukaemia 2A60 Phase 3 [5]
ASTX727 DM4HK8Z Chronic myelogenous leukaemia 2A20.0 Phase 3 [6]
PMID27376512-Compound-PG-11047 DM5K4YF N. A. N. A. Patented [2]
PMID27376512-Compound-PG-11048 DM3U7RN N. A. N. A. Patented [2]
PMID27376512-Compound-MTC-434 DM70CTE N. A. N. A. Patented [2]
PMID27376512-Compound-CROs DMBFUTL N. A. N. A. Patented [2]
(L-)-S-adenosyl-L-homocysteine DMDUN83 Discovery agent N.A. Investigative [3]
NSC-622445 DME35CB Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA [cytosine-5]-methyltransferase (DNMT) TTHVCUP NOUNIPROTAC Inhibitor [1]
DNA [cytosine-5]-methyltransferase 3B (DNMT3B) TT6VZ78 DNM3B_HUMAN Inhibitor [1]

References

1 Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
2 DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
3 Constrained (l-)-S-adenosyl-l-homocysteine (SAH) analogues as DNA methyltransferase inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2742-6.
4 The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid l... Leukemia. 2009 Jun;23(6):1019-28.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)